Literature DB >> 1338232

Brachytherapy for malignant recurrent and untreated gliomas.

P W Hitchon1, J C VanGilder, B C Wen, S Jani.   

Abstract

Twelve consecutive patients with recurrent malignant glioma were treated with brachytherapy. Thereafter, a prospective randomized study involving 35 patients was undertaken. Although additional study is necessary, preliminary recommendation calls for treatment at diagnosis rather than at recurrence.

Entities:  

Mesh：

Year:  1992        PMID： 1338232     DOI： 10.1159/000098937

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN： 1011-6125            Impact factor:   1.875


  4 in total

1.  Receipt of brachytherapy is an independent predictor of survival in glioblastoma in the Surveillance, Epidemiology, and End Results database.

Authors:  Jiri Bartek; Ali A Alattar; Sanjay Dhawan; Jun Ma; Tomoyuki Koga; Peter Nakaji; Kathryn E Dusenbery; Clark C Chen
Journal:  J Neurooncol       Date:  2019-08-30       Impact factor: 4.130

2.  Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.

Authors:  A Boiardi; M Eoli; A Salmaggi; B Zappacosta; L Fariselli; I Milanesi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

3.  The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.

Authors:  H Brem; M G Ewend; S Piantadosi; J Greenhoot; P C Burger; M Sisti
Journal:  J Neurooncol       Date:  1995-11       Impact factor: 4.130

4.  Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III.

Authors:  B Suchorska; C Hamisch; H Treuer; K Mahnkopf; R E Lehrke; M Kocher; M I Ruge; J Voges
Journal:  J Neurooncol       Date:  2016-07-15       Impact factor: 4.130
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.